HROW Quote, Financials, Valuation and Earnings

Merck & has a net margin of -37.17% compared to Harrow's net margin of 32.71%. Harrow's return on equity of -35.99% beat Merck &'s return on equity of 39.02%.

Harrow has a consensus price target of $59.03, signalling upside risk potential of 70.84%. On the other hand Merck & has an analysts' consensus of $101.79 which suggests that it could grow by 23.48%. Given that Harrow has higher upside potential than Merck &, analysts believe Harrow is more attractive than Merck &.

Harrow has a beta of 0.407, which suggesting that the stock is 59.3% less volatile than S&P 500. In comparison Merck & has a beta of 0.389, suggesting its less volatile than the S&P 500 by 61.063%.

Harrow has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.88% to investors and pays a quarterly dividend of $0.81 per share. Harrow pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Harrow quarterly revenues are $47.8M, which are smaller than Merck & quarterly revenues of $15.5B. Harrow's net income of -$17.8M is lower than Merck &'s net income of $5.1B. Notably, Harrow's price-to-earnings ratio is -- while Merck &'s PE ratio is 12.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harrow is 5.80x versus 3.27x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -37.17% compared to Harrow's net margin of -49.65%. Harrow's return on equity of -35.99% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Harrow has a consensus price target of $59.03, signalling upside risk potential of 70.84%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.62%. Given that Harrow has higher upside potential than NovaBay Pharmaceuticals, analysts believe Harrow is more attractive than NovaBay Pharmaceuticals.

Harrow has a beta of 0.407, which suggesting that the stock is 59.3% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Harrow has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harrow pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Harrow quarterly revenues are $47.8M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Harrow's net income of -$17.8M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Harrow's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harrow is 5.80x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -37.17% compared to Harrow's net margin of 21.63%. Harrow's return on equity of -35.99% beat Pfizer's return on equity of 8.72%.

Harrow has a consensus price target of $59.03, signalling upside risk potential of 70.84%. On the other hand Pfizer has an analysts' consensus of $29.23 which suggests that it could grow by 18.77%. Given that Harrow has higher upside potential than Pfizer, analysts believe Harrow is more attractive than Pfizer.

Harrow has a beta of 0.407, which suggesting that the stock is 59.3% less volatile than S&P 500. In comparison Pfizer has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.783%.

Harrow has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.91% to investors and pays a quarterly dividend of $0.43 per share. Harrow pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Harrow quarterly revenues are $47.8M, which are smaller than Pfizer quarterly revenues of $13.7B. Harrow's net income of -$17.8M is lower than Pfizer's net income of $3B. Notably, Harrow's price-to-earnings ratio is -- while Pfizer's PE ratio is 17.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harrow is 5.80x versus 2.25x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Vir Biotechnology has a net margin of -37.17% compared to Harrow's net margin of -6742.75%. Harrow's return on equity of -35.99% beat Vir Biotechnology's return on equity of -45.02%.

Harrow has a consensus price target of $59.03, signalling upside risk potential of 70.84%. On the other hand Vir Biotechnology has an analysts' consensus of $17.63 which suggests that it could grow by 225.79%. Given that Vir Biotechnology has higher upside potential than Harrow, analysts believe Vir Biotechnology is more attractive than Harrow.

Harrow has a beta of 0.407, which suggesting that the stock is 59.3% less volatile than S&P 500. In comparison Vir Biotechnology has a beta of 1.224, suggesting its more volatile than the S&P 500 by 22.375%.

Harrow has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vir Biotechnology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harrow pays -- of its earnings as a dividend. Vir Biotechnology pays out -- of its earnings as a dividend.

Harrow quarterly revenues are $47.8M, which are larger than Vir Biotechnology quarterly revenues of $1.8M. Harrow's net income of -$17.8M is higher than Vir Biotechnology's net income of -$121M. Notably, Harrow's price-to-earnings ratio is -- while Vir Biotechnology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harrow is 5.80x versus 51.74x for Vir Biotechnology. Usually stocks with elevated PS ratios are considered overvalued.